Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Saved in:
Bibliographic Details
Title: Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.
Authors: Khurana S; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. surender.khurana@fda.hhs.gov., Posadas O; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Kardava L; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Coyle EM; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Ravichandran S; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., Grubbs G; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA., McConnell R; Critical Care Medicine, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA., Rouphael N; Hope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, USA., Poliquin G; Public Health Agency of Canada, Children's Hospital Research Institute, Winnipeg, Manitoba, Canada., Langley JM; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada., Chu E; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Follmann DA; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Shang X; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Li Y; Department of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Moir S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Davey RT Jr; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Source: Nature immunology [Nat Immunol] 2026 May; Vol. 27 (5), pp. 1053-1065. Date of Electronic Publication: 2026 Mar 19.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1529-2916
DOI:10.1038/s41590-026-02459-w